Browse > Article
http://dx.doi.org/10.22722/KJPM.2022.30.2.165

The Effect of Second-Generation Antipsychotics Administration for 1-Year on the Platelet Activities in Patients With Schizophrenia: Retrospective Study  

Yoon-Seok, Oh (Department of Psychiatry, College of Medicine, Konyang University)
Jong Wook, Lee (Konyang University Myunggok Medical Research Institute)
Hong-Seok, Oh (Department of Psychiatry, College of Medicine, Konyang University)
Seung-Jun, Kim (Department of Psychiatry, College of Medicine, Konyang University)
Na-Hyun, Lee (Department of Psychiatry, College of Medicine, Konyang University)
Woo Young, Im (Department of Psychiatry, College of Medicine, Konyang University)
Ji-Woong, Kim (Department of Psychiatry, College of Medicine, Konyang University)
Publication Information
Korean Journal of Psychosomatic Medicine / v.30, no.2, 2022 , pp. 165-171 More about this Journal
Abstract
Objectives : This study was conducted to investigate the effect of 1-year administration of second-generation antipsychotics (SGAs) on the platelet activity in patients with schizophrenia through a retrospective review of the medical records. Methods : The mean platelet component (MPC) value was used as an index of the platelet activity. The included subjects (N=24) were the patients who were confirmed to have taken SGAs continuously for one year after the first MPC measurement had been performed. The change of MPC was verified through a paired sample t-test. Results : The result revealed that the mean MPC value was significantly decreased from 26.5±1.4 g/dL to 25.6±1.8 g/dL after 1-year administration of SGAs from the time of the first MPC measurement. Conclusions : This study suggests that 1-year administration of SGAs may be related with increased platelet activity, and that close monitoring for risks such as cerebrovascular/cardiovascular or thromboembolic diseases may be necessary during SGAs treatment in clinical practice.
Keywords
Second-generation antipsychotics; Mean platelet component; Platelet activity; Schizophrenia; Cerebrovascular/cardiovascular diseases;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Masopust J, Maly R, Valis M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry and Clinical Neurosciences 2012;66:541-552.    DOI
2 Parker C, Coupland C, Cox JH. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ 2010;341:c4245.    DOI
3 Kim HA, Lee JW, Kim SJ, Oh HS, Im WY, Kim JW. Second-generation antipsychotics activate platelets in antipsychotic-naive and antipsychotic-free patients with schizophrenia: a retrospective study. Int J Psychiatry Med 2020;55:105-113.    DOI
4 Kim HA, Lee JW, Kim SJ, Oh HS, Im WY, Kim JW. Clozapine administration potentiate platelet activation in patients with schizophrenia: retrospective study. Korean J Psychosomatic Med 2018;26:188-193.    DOI
5 Chapman ES, Sorette M, Hetherington E, Zelmanovic D, Kling G, Dugailliez J, Pujol-Moix N, Okrongly D. A rapid, automated flow cytometric method to measure activated degranulated platelets by density determination. Thromb Haemost 2003;89:1004-1015.    DOI
6 Macey MG, Carty E, Webb L, Chapman ES, Zelmanovic D, Okrongly D, Rampton DS, Newland AC. Use of mean platelet component to measure platelet activation on the ADVIA 120 haematology system. Cytometry 1999;38:250-255.    DOI
7 Semiz M, Yucel H, Kavakci O, Yildirim O, Zorlu A, Yilmaz MB, Kucukdurmaz Z, Canan F. Atypical antipsychotic use is an independent predictor for the increased mean platelet volume in patients with schizophrenia: a preliminary study. J Res Med Sci 2013;18:561-566. 
8 Jang EJ, Lee JW, Kim SJ, Oh HS, Lee Nh, Im WY, Kim JW. A retrospective study on the effect of 1-year clozapine administration on platelet activity in patients with schizophrenia or schizoaffective disorder. Korean J Psychosomatic Med 2020;28:36-41.    DOI
9 Kim DS, Ryu SH, Lee JW, Kim YD, Choi YC. Mean platelet component to measure platelet activation in ischemic stroke: preliminary study. J Korean Neurol Assoc 2002;20:223-226. 
10 Pawlus J, Holub M, Kozuch M, Dabrowska M, Dobrzycki S. Serum myeloperoxidase levels and platelet activation parameters as diagnostic and prognostic markers in the course of coronary disease. Int J Lab Hematol 201032:320-328. 
11 Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005;150:1115-1121.    DOI
12 Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, Thapa-Chhetri N, Fornaro M, Gallicchio D, Collantoni E, Pigato G, Favaro A, Monaco F, Kohler C, Vancampfort D, Ward PB, Gaughran F, Carvalho AF, Stubbs B. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017;16:163-180.    DOI
13 Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14:119-136.    DOI
14 Castillo-Sanchez M, Escurriola MF, Sanmartin MIF, Solntseva I, Baquero DB, Arno AG. Cardiovascular disease and mortality in people with schizophrenia or antipsychotic treatment: a cohort study in primary care. Psychiatry Res 2021 114233. Epub 2021 Oct 10. 
15 Roberts CK and Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009;84:705-712.    DOI
16 Santilli F, Lapenna D, La Barba S, Davi G. Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. Free Radic Biol Med 2015;80:101-110.    DOI
17 Hagg S, Bate A, Stahl M, spigset O. Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions. Drug Saf 2008;31:685-694.    DOI
18 Jonsson AK, Schill J, Olsson H, Spigset O, Hagg S. Venous thromboembolism during treatment with antipsychotics: a review of current evidence. CNS Drugs 2018;32:47-64.    DOI
19 Axelsson S, Hagg S, Eriksson AC, Lindahl TL, Whiss PA. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol 2007;34:775-780.   DOI
20 Hert MD, Detraux J, Winkel RV, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with anti-psychotic drugs. Nat Rev Endocrinol 2011;8:114-126.    DOI
21 Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002;16:765-776.    DOI